Inflammatory bowel disease

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
7 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
J Anti-infectives (ATC J) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Aminoglycoside 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase II: 1 Phase IV: 2 Phase I: 2 Phase I (Other): 2

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    GENTAMICIN SULFATE
    2024-513330-38-00 1 country 2026 n=45
    Recruiting

Phase IV

2 trials
  • Amsterdam UMC Stichting Academic
    INFLIXIMAB
    2024-517171-20-00 1 country n=158
    Ended
  • Belgian IBD Research and Development Academic
    IMP not specified
    2023-508166-15-00 1 country 2024 n=275
    Ended

Phase I

2 trials
  • Coultreon Biopharma Commercial
    IMP not specified
    2025-522571-28-00 1 country 2025 n=96
    Recruiting
  • Lmito Therapeutics Inc. Commercial
    IMP not specified
    2024-519180-17-00 1 country n=72
    Pending

Phase I (Other)

2 trials
  • Abivax Commercial
    IMP not specified
    2023-505297-15-00 1 country 2023 n=36
    Ended
  • Universitair Medisch Centrum Groningen Academic
    IMP not specified
    2024-513390-50-00 1 country 2024 n=33
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Coultreon Biopharma Commercial 1 Phase I 1
Lmito Therapeutics Inc. Commercial 1 Phase I 0
Abivax Commercial 1 Phase I (Other) 0
Universitair Medisch Centrum Groningen Academic 1 Phase I (Other) 1
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
Amsterdam UMC Stichting Academic 1 Phase IV 0
Belgian IBD Research and Development Academic 1 Phase IV 0
New trials by year
2023
1
2024
2
2025
1
2026
1
← All indication landscapes